Clinical topic guides
Structured explainers frame ibogaine and opioid-use evidence alongside heroin dependence, including the broader context in ibogaine for opioid addiction. The goal is orientation, not a treatment directive.
Independent information services
Services
Ibogaine and heroin dependence require careful context. Long Waypoint 72 organizes guides, comparisons, research summaries, and decision frameworks for people who want to distinguish early research, known risks, and established options.
- Evidence before claimsResearch is separated from conclusions it cannot yet support.
- Safety clarityRisk and uncertainty stay visible, not buried in fine print.
- Plain languageComplex topics are organized for affected people, families, and researchers.
What we provide
Information that keeps the distinctions intact.
These are informational services, not medical or clinical services. They are designed to make a difficult subject easier to examine without converting uncertainty into a promise.
Research versus established care
Comparison pages distinguish exploratory claims from established treatment approaches. For a plain-language starting point, the SAMHSA overview of medications for substance use disorders describes recognized medication options for opioid use disorder.
Trials, questions, and limits
We collect questions that help readers assess methods, endpoints, follow-up, and eligibility. Our material on ibogaine clinical trials in Texas is one route into the practical questions research can and cannot answer.
Connected topic explainers
Related concerns can change how people read a claim. The brain injury context for ibogaine and our notes on ibogaine treatment claims for depression help preserve those boundaries.
A practical reading system
A framework for assessing a difficult claim.
Our main ibogaine and opioid-use evidence overview begins with a simple premise: a treatment story, a biological mechanism, and a clinical finding are not the same thing. The framework below helps keep that distinction visible.
- Identify the claim. Is it about withdrawal, craving, safety, long-term outcomes, or something else?
- Locate the evidence. Consider study design, number of participants, comparison groups, and follow-up.
- Read the risk context. Ibogaine has been associated with serious cardiac concerns; background on the drug itself is summarized in the ibogaine reference entry.
- Separate information from action. Evidence review does not replace individualized medical assessment or emergency support.
Comparison lens
What this resource helps readers compare.
The point is not to rank personal experiences. It is to show where an information claim belongs, what it leaves unresolved, and why safety questions remain central.
| Question area | What the resource examines | What it does not do |
|---|---|---|
| Ibogaine research | Study language, methods, reported outcomes, and uncertainty. | Declare ibogaine safe, effective, or appropriate for any person. |
| Heroin dependence | How opioid-use evidence and care options are discussed in public information. | Provide diagnosis, detoxification planning, or medical supervision. |
| Related conditions | How claims may extend to alcohol use, depression, or neurological injury. | Assume evidence in one area transfers to another. |
Plain-language definitions
Terms such as opioid use disorder, withdrawal, abstinence, adverse event, and follow-up can carry different meanings in different contexts. We clarify the terms before comparing the claims.
Adjacent claim review
Readers can compare how ibogaine is discussed across alcohol-related material, including ibogaine and alcohol addiction and a separate review of claims around extreme alcoholism, without treating those topics as interchangeable with heroin dependence.
FAQ collection
Clear answers about the scope of this work.
Long Waypoint 72 explains how it approaches difficult health information. For the purpose and principles behind the resource, see our approach and mission.
Are these medical or treatment services?
No. Long Waypoint 72 is an independent information resource, not a clinic, medical provider, or licensed treatment center. It does not diagnose, prescribe, screen, or arrange treatment.
Why include established options in an ibogaine brief?
Because a clinical brief needs a real comparison point. The National Institute on Drug Abuse summary of medications for opioid use disorder provides useful context for discussing established approaches without presenting this resource as medical guidance.
Does information about ibogaine apply to every substance-use concern?
No. Different populations, conditions, substances, and study designs raise different questions. Our overview of ibogaine as a psychedelic drug is offered as context, not as a basis for broad conclusions.
Who is this material for?
It is for people affected by opioid use disorder, families, researchers, and policymakers who need clear context on ibogaine without overstating what the evidence can establish.
“The service is clarity: early research, known risks, and established options held in the same view.”